id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-P-6045-0019,FDA,FDA-2019-P-6045,180-day Interim Response to the Wacker Chemical Corporation,Other,Letter(s),2020-06-12T04:00:00Z,2020,6,2020-06-12T04:00:00Z,,2022-01-27T02:00:27Z,,0,0,09000064846ea0f7
FDA-2019-P-6045-0017,FDA,FDA-2019-P-6045,"Appendix A and B from Hyman, Phelps and McNamara, P.C. on behalf of Wacker Chemical Corporation",Supporting & Related Material,Background Material,2020-02-03T05:00:00Z,2020,2,,,2020-02-03T16:07:56Z,,0,0,0900006484321903
FDA-2019-P-6045-0016,FDA,FDA-2019-P-6045,"Cover letter from Hyman, Phelps and McNamara, P.C. on behalf of Wacker Chemical Corporation",Supporting & Related Material,Background Material,2020-02-03T05:00:00Z,2020,2,,,2020-02-03T16:08:11Z,,0,0,0900006484321902
FDA-2019-P-6045-0018,FDA,FDA-2019-P-6045,"Alpha-Cyclodextrin Attenuates the Glycemic and Insulinemic Impact of White Bread in Healthy Male Volunteers from Hyman, Phelps and McNamara, P.C. on behalf of Wacker Chemical Corporation",Supporting & Related Material,Background Material,2020-02-03T05:00:00Z,2020,2,,,2020-02-03T16:07:44Z,,0,0,0900006484321904